- Aptamers are engineered molecules that can bind to specific target compounds with high affinity and selectivity, making them valuable tools in various applications.
- Achieving absolute specificity, or binding to a single compound exclusively, is challenging due to the structural similarities among molecules. However, aptamers can still exhibit high selectivity, allowing them to differentiate between closely related compounds.
- Aptamers find applications in medical diagnostics, therapeutics, and environmental monitoring, where their selectivity is crucial for accurate and effective results. Continued research in aptamer design holds promise for improving their specificity in practical use cases.
Aptamers are a class of molecules that have garnered considerable attention in the field of molecular biology and diagnostics. Often referred to as “chemical antibodies,” these short, single-stranded DNA or RNA sequences possess a remarkable ability to bind to specific target molecules with high affinity. While aptamers are recognized for their unique binding capabilities, one question that has intrigued researchers is whether aptamers can achieve the level of specificity required to selectively bind to a single compound. In this blog, we explore the world of aptamers, their potential for selectivity, and the implications of this remarkable specificity for various applications.
Aptamers are molecules that can be engineered to possess specific three-dimensional shapes, enabling them to selectively bind to target molecules.
Traditionally, the development of aptamers involves a process known as systematic evolution of ligands by exponential enrichment (SELEX). During SELEX, a vast library of random nucleic acid sequences undergoes iterative rounds of selection, amplification, and enrichment to generate specific aptamer sequences. However, this process does not account for sequences that exhibit weak binding to non-target molecules. Consequently, the resulting aptamers may lack the requisite selectivity and specificity for most applications.
NeoVentures has pioneered and patented the Neomers approach, representing the next generation of aptamer selection. This method allows for screening the same library of random sequences against the target molecule as well as all potential off-target molecules. As a result, the resulting aptamer sequences are guaranteed to exhibit a high degree of specificity and selectivity for the intended target.
Selectivity vs. Specificity
Selectivity and specificity are two terms often used interchangeably, but they have distinct meanings in the context of aptamers.
Selectivity: Selectivity refers to the ability of an aptamer to distinguish its target molecule from other similar molecules. Aptamers can be highly selective, binding to their intended target while ignoring closely related compounds. This selectivity is critical in applications such as medical diagnostics, where differentiation between different biomarkers is crucial.
Specificity: Specificity goes beyond selectivity by necessitating that the aptamer exclusively binds to a single compound without any cross-reactivity with other molecules. Attaining absolute specificity can be demanding, as it requires an aptamer to exhibit both a high degree of selectivity and pinpoint accuracy in its binding. This is where the Neomers selection method surpasses SELEX, as it can attain a level of specificity that SELEX cannot achieve.
The Quest for Absolute Specificity
The primary challenge in developing aptamers with absolute specificity lies in the structural similarities that often exist between target and non-target molecules. For aptamers to be highly specific, researchers must identify unique binding sites on the target molecule, which differentiates it from all other compounds. NeoVentures has over 20 years of experience in selecting and identifying aptamers that demonstrate unparalleled specificity, overcoming the intricate structural resemblances between target and non-target molecules. Our team of dedicated scientists employs cutting-edge technologies and innovative methodologies to meticulously characterize the unique binding sites on target molecules, ensuring that the developed aptamers exhibit exceptional selectivity and accuracy. This extensive expertise positions NeoVentures at the forefront of aptamer development, facilitating the creation of highly specific molecular recognition tools for diverse applications in diagnostics, therapeutics, and beyond.
Applications and Implications
- Medical Diagnostics: Aptamers are being actively explored as molecular recognition elements for diagnostic assays, such as detecting specific proteins or nucleic acids in patient samples. While absolute specificity may not always be necessary, high selectivity is vital to ensure accurate results and minimize false positives.
- Therapeutics: In the realm of drug delivery and precision medicine, aptamers show promise. Aptamers can be used to target specific proteins on the surface of cancer cells, for example, allowing for highly targeted and precise treatment. Although absolute specificity is challenging to achieve, high selectivity can still lead to effective therapies.
- Environmental Monitoring: Aptamers can be employed to detect and quantify environmental contaminants or pathogens. In these applications, selectivity is paramount, as there is often a range of similar molecules in the environment that need to be distinguished from the target of interest.
The specificity of aptamers, or their ability to bind selectively to a single compound, remains a challenge for researchers. While it is difficult to achieve absolute specificity due to the structural similarities of molecules, aptamers can exhibit high selectivity, making them valuable tools in a wide range of applications, from diagnostics to therapeutics and environmental monitoring. As our understanding of aptamer design and development advances, we can expect continued progress in harnessing the remarkable specificity of aptamers for various practical purposes.
Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases.